Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flu vaccines pass €1 billion in Sanofi-Aventis's Q4

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis has reported a 10% increase in its fourth-quarter net income as sales of its influenza vaccines grew to almost €1.1 billion. The French firm's human vaccines business expanded by 65% in the quarter, pushing group net income to €1.8 billion. More to follow.

You may also be interested in...

Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III

Reports about delays to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.

WHO’s Cooke Takes Lead At EMA

Currently serving at the WHO, Emer Cooke is set to return to EMA this month as executive director. The EMA’s management board has brought in new leadership to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.

AAM Welcomes Biosimilar Access Bill

A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts